<DOC>
	<DOCNO>NCT00262184</DOCNO>
	<brief_summary>Consumption soy-based food associate number health benefit , include low risk cardiovascular disease , breast prostate cancer , attenuate menopausal symptom prevention bone loss age . In order investigate effect isoflavone bone mineral density ( BMD ) Taiwan woman postmenopausal osteopenia , Taiwan Isoflavone Multicentric Enrollment Study ( TIMS ) design .</brief_summary>
	<brief_title>A Taiwan Isoflavone Multicenter Study ( TIMS )</brief_title>
	<detailed_description>Consumption soy-based food associate number health benefit , include low risk cardiovascular disease , breast prostate cancer , attenuate menopausal symptom prevention bone loss age . In order investigate effect isoflavone bone mineral density ( BMD ) Taiwan woman postmenopausal osteopenia , Taiwan Isoflavone Multicentric Enrollment Study ( TIMS ) design . Included study Taiwanese , postmenopausal woman age &gt; 45 &lt; 65 year , menopaused least 12 month le 10 year . Three medical center participate enroll 140 woman every center . Inclusion basis lumbar bone mineral density ( BMD ) low 1 SD compare young age woman ( T score ) DXA . Women prevalent fracture ( kind fragility fracture , vertebral nonvertebral fracture ) exclude well present secondary osteoporosis treat medication could affect bone metabolism . This study design 2-year , double-blind , placebo-controlled , two-arm , parallel group study randomize woman oral administration 300 mg isoflavone aglycone/day placebo . All patient receive daily supplement 600 mg calcium 300U Vit D3 . The primary endpoint study evaluate effect isoflavone aglycone BMD . The secondary endpoint study evaluate effect Isoflavone aglycone metabolic indicator osteoporosis , blood pressure , blood sugar insulin level , insulin resistance ( HOMA-IR ) , lipid profile , marker arthrosclerosis ( adiponectin hsCRP ) , myocardial infarction rate , cardiovascular mortality , cerebrovascular accident rate , cerebrovascular mortality , cause mortality symptomatic relief menopausal syndrome , BMD read do concomitantly 3 expert , e.g . one participate center . All blood test urine examination do one center control quality . The blood count , biochemistry ( include : GOT , GPT , BUN , creatinine ) , mammography , gynecological sonography ( especially uterus ) perform monitor side effect . Power calculation base hypothesis isoflavone-treated patient would get 2.5 % benefit BMD placebo-treated patient postmenopausal woman . Statistical test design power 80 % , type I error equal 5 % . This study verify hypothesis isoflavone significantly increase BMD Asian postmenopausal osteopenic woman .</detailed_description>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>1 . The postmenopausal woman menopaused least 12 month le 10 year . 2 . The postmenopausal woman age &gt; 45 &lt; 65 year . 3 . For do hysterectomy age 50 60 , FSH &gt; 40 IU/l Estradiol &lt; 40 pg/ml . 4 . Bone mineral density ( BMD ) lumbar spine L2L4 ( AP view ) low 1 SD compare young age woman ( T score &lt; 1 ) 5 . BMI , 18.5kg/m2 30 kg/m2 6 . Willingness comply protocol sign write Informed Consent . 1 . Any prevalent vertebral , hip wrist fracture . 2 . Secondary osteoporosis , osteomalacia , Paget 's disease bone , multiple myeloma , bone metastasis . 3 . Hormonal replacement therapy ( HRT ) SERM within previous 3 month 4 . Phytoestrogen treatment within previous 3 month 5 . Fluoride treatment within previous 6 month 6 . Bisphosphate treatment within previous 12 month 7 . Calcitonin treatment within previous 6 month 8 . Any treatment affect bone mineral density within previous 6 month 9 . Chronic systemic corticosteroid treatment within previous 6 month 10 . History Gynecological cancer breast cancer 11 . Cervical smear class III IV , accord Bethesda system . 12 . Undiagnosed vaginal bleeding . 13 . Known suspected estrogendependent tumor , fibroid endometrial polyp 14 . Significant Pathological endometrial hyperplasia 15 . Active major psychiatric disorder 16 . Alcoholism drug abuse 17 . Known cardiovascular , cerebrovascular peripheral vascular disorder ( e.g . thrombophlebitis , thromboembolism ) 18 . Uncontrolled Diabetes HbA1C &gt; 10 % 19 . Uncontrolled hypertension blood pressure &gt; 180/100 mmHg 20 . Uncontrolled hypothyroidism 21 . Any renal disease serum creatinine &gt; 2mg/dl 22 . Abnormal liver function SALT SAST value &gt; 2fold upper limit</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Post-Menopausal osteopenia</keyword>
</DOC>